SEC Comment Letter for aTYR PHARMA INC (ATYR) (CIK 0001339970) (ATYR) — Jan 23, 2020
aTYR PHARMA INC (ATYR) (CIK 0001339970)
Date: Jan. 23, 2020 · CIK: 0001339970 · Accession: 0000000000-20-000612
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235951
Letter
January 23, 2020 Sanjay Shukla President and Chief Executive Officer aTyr Pharma, Inc. 3545 John Hopkins Court, Suite 250 San Diego, CA 92121 Re:aTyr Pharma, Inc. Registration Statement on Form S-1 Filed January 17, 2020 File No. 333-235951 Dear Mr. Shukla: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sean Clayton
Show Raw Text
January 23, 2020
Sanjay Shukla
President and Chief Executive Officer
aTyr Pharma, Inc.
3545 John Hopkins Court, Suite 250
San Diego, CA 92121
Re:aTyr Pharma, Inc.
Registration Statement on Form S-1
Filed January 17, 2020
File No. 333-235951
Dear Mr. Shukla:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sean Clayton